International Journal of Laboratory Hematology · 2014 · 22 citations · 27 references
MedicineHematologyPathologyCellular PathologyHematologic OncologyHematopathologyCell CharacterizationHematologic MalignanciesLymphoid NeoplasmsLymphoid TumorsTumor CharacterizationB-cell LeukemiaDiagnostic Uncertainty AnalysisDiagnostic Uncertainty CriteriaDiagnostic Uncertainty QuantificationDifferential Diagnosis CriteriaFlow Cytometry ImmunophenotypingHematologic Malignancy DiagnosticsLeukemia Diagnostics
INTRODUCTION: Chronic lymphocytic leukemia is usually diagnosed through the characteristic morphology/immunophenotype of the lymphocytes, but some CLL cases remain atypical resulting in diagnostic uncertainty. METHODS: Using flow cytometry analysis, we investigated the expression of CDs160/200 on B cells from 124 patients (82 CLL, 42 other B-cell neoplasms) and nine controls. CDs160/200 measurements were determined as a ratio of the mean fluorescence intensities of leukemic cells/controls and were considered positive when the ratios were ≥2 and 20, respectively. RESULTS: Sixty and 83% CLL expressed CDs160/200 as compared to 5% and 10% of other B-cell neoplasms, respectively. None of the controls showed CDs160/200 expressions. Combination of both markers was observed in 55% of CLL but only in 2% of other B-cell neoplasms, and absence of both markers occurred in 12% of CLL but in 86% of other B-cell neoplasms. CONCLUSION: CDs160/200 were associated with markers of the gold standard 'Matutes score' and could be useful markers to differentiate atypical CLL from other B-cell neoplasms in the absence of available biopsies or cytogenetics and molecular studies.
27
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
J L Binet, Ariane Auquier, Guillaume Dighiero et al. · Cancer · 1981 · 1.8K citations
Medicine, Hematology, Oncology +15